RENSSELAER, N.Y.--(BUSINESS WIRE)--ConSynance Therapeutics, Inc. announced today that collaborator Dr. Nicholas Barnes presented data at the International Society for Serotonin Research in Cork, Ireland showing the potential of CSTI-300 as an efficacious and well tolerated drug candidate for the treatment of Irritable Bowel Syndrome with diarrhea (IBS-D).
IBS is a chronic and sometimes disabling bowel disorder that is often associated with severe abdominal pain. It is estimated that 10-12% of all adults are affected. There currently is no adequate treatment for IBS-D and no approved therapeutic for the treatment of IBS with alternating symptoms between diarrhea and constipation (IBS-mixed or IBS-M).
The data presented by Dr. Barnes showed that CSTI-300 is a selective serotonin receptor-3 (5-HT3) partial agonist that is clearly differentiated from an approved therapeutic, alosetron, a 5-HT3 antagonist. Alosetron is only indicated for severe IBS-D and is associated with adverse effects of severe constipation and ischemic colitis. CSTI-300’s partial agonist mechanism is predicted to deliver efficacy with an improved the side effect profile. Consistent with this rationale, orally administered CSTI-300 was found to be efficacious in a clinically validated rat model of IBS-D and have excellent tolerability in multiple large animal models. CSTI-300 possesses a large therapeutic index, evidence for a better side effect profile, acceptable pharmaceutical properties and, thus, the potential to treat a wider spectrum of IBS-D and IBS-M patients. Investigational New Drug (IND)-enabling studies have just commenced for CSTI-300 in preparation for a clinical study.
"We believe that CSTI-300's unique mechanism of action and positive data from multiple animal studies support the potential for this novel drug to offer superior relief to IBS patients” said Peter Guzzo, PhD, CEO of ConSynance.
About ConSynance Therapeutics, Inc.
ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. The company’s pipeline includes innovative treatments for nonalcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. ConSynance are collaborating with Chengdu SciMount Pharmatech Co., Ltd., a drug discovery company based in China, on the preclinical studies for the IBS project. ConSynance is seeking corporate partners to help accelerate the development of its programs to market. www.consynance.com
